Table 1.
Placebo (n=22) | DRCFI (n=20) | |
---|---|---|
Age (years)* | 59.5 (13.2) | 70 (5.6) |
Female—number (%) | 13 (59.1) | 10 (50) |
FEV1 (l) | 1.47 (0.73) | 1.57 (0.77) |
FEV1 per cent predicted (%) | 53.1 (22.7) | 60.7 (24.1) |
Sputum Pseudomonas aeruginosa bacterial density (log10 CFU/g) | 5.9 (2.7) | 6.5 (2.3) |
Other sputum organisms present in >1 subject† | Klebsiella spp. Ochrobactrum anthropi |
Klebsiella spp. |
Comorbidities—n | ||
Ischaemic heart disease | 9 | 10 |
Hypertension | 6 | 9 |
Diabetes mellitus | 2 | 0 |
Cerebrovascular disease | 1 | 0 |
Medications—n | ||
Maintenance oral macrolides | 4 | 5 |
Inhaled corticosteroids | 4 | 6 |
Combination inhalers (ICS/LABA) | 9 | 11 |
Inhaled LABA | 2 | 2 |
Inhaled SABA | 13 | 10 |
Inhaled LA anticholinergic | 5 | 7 |
Inhaled SA anticholinergic | 4 | 1 |
Prednisone | 1 | 1 |
Inhaled mannitol | 2 | 2 |
Prior smokers—n | 0 | 1 |
Values are mean (SD) except where otherwise indicated.
*p<0.01 for the comparison between groups for age; there were no significant differences between groups for other variables.
†n=2 for each of these organisms.
CFU, colony forming unit; DRCFI, dual release ciprofloxacin for inhalation, FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroids, LA, long-acting; LABA, long-acting β-agonists, SA, short-acting; SABA, short-acting β-agonists.